Case report

Optic nerve head reactive retinal astrocytic tumor treated with photodynamic therapy

Alex C. Onishi, Lee M. Jampol, Amani A. Fawzi *

Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, 645 N. Michigan Avenue, Suite 440, Chicago, IL, 60611, USA

ARTICLE INFO

Keywords:
Reactive retinal astrocytic tumor
Vasoproliferative retinal tumor
Photodynamic therapy

ABSTRACT

Purpose: To describe the unusual presentation and the treatment course of a case of bilateral optic nerve head reactive retinal astrocytic tumor (RRAT).

Observations: A 29-year-old woman with bilateral optic disc masses presented with declining vision refractory to anti-vascular endothelial growth factor (VEGF) injections. After total loss of vision in her left eye, diagnostic enucleation and histopathology was consistent with RRAT. Staged photodynamic therapy (PDT) treatments over a period of four months in the better seeing eye resulted in stabilization of vision, improvement in intraretinal and subretinal fluid, and shrinkage of the optic disc mass.

Conclusions: In this unusual case of bilateral vision-threatening optic nerve head RRAT that were refractory to multiple therapies including anti-VEGF injections, PDT demonstrated safety and efficacy. Diagnostic work-up included whole exome sequencing (WES) that was negative for mutations in genes related to von-Hippel-Lindau (VHL), neurofibromatosis, tuberous sclerosis, and hypoxia-inducible factor (HIF)-2α.

1. Introduction

Reactive retinal astrocytic tumors (RRAT), also known as vasoproliferative tumors of the retina (VPTR), were originally called “presumed acquired retinal hemangiomas” by Shields et al.1 Subsequently, Shields et al. renamed these tumors “vasoproliferative retinal tumors” based on histopathology demonstrating that these lesions were not true hemangiomas.2 They differentiated primary tumors (approximately 75% of cases) and those secondary to ocular diseases such as uveitis (approximately 25% of cases). The majority of these tumors were located in the retinal periphery, most often in the inferior, temporal, or inferotemporal regions, with uncommon bilateral involvement. While these tumors have rarely been reported at the optic disc, they were usually unilateral,2,3 RRAT typically appear as pink-to-yellow lesions, and are associated with retinal exudates and edema, which may lead to visual complaints including photopsias.4,5

More recently, Poole Perry et al.5 argued for a change in the nomenclature based on the histopathology of four enucleated eyes demonstrating glial fibrillary acidic protein (GFAP)-positive spindle cells with a relatively sparse microvasculature, suggesting a predominance of reactive astrocytes. As a result, they proposed the term “reactive retinal astrocytic tumor,” the name utilized in the current report. Their naming suggestion has been supported by subsequent gene expression profiling.7

We discuss an unusual case of a young woman presenting with progressive bilateral vision loss and bilateral optic nerve head masses. Whole exome sequencing (WES) was negative for mutations in von Hippel-Lindau (VHL) and hypoxia-inducible factor (HIF)-2α. Histopathology was consistent with RRAT. The remaining eye was treated successfully with photodynamic therapy (PDT) after progression to recalcitrant macular exudation despite high-frequency intravitreal anti-vascular endothelial growth factor (VEGF) and intravitreal steroid therapy.

1.1. Case report

A 29-year-old woman with declining vision in her left eye was initially seen by us in 2011 with a 15-year history of headaches associated with bilateral optic nerve head swelling and possible masses (Fig. 1). Her visual acuity was 20/20 OD and 20/150 OS. At the age of 14, she had been diagnosed with pseudotumor cerebri, and had undergone an extensive negative work-up and a left-sided optic nerve sheath fenestration without improvement.

Our initial working diagnosis was VHL syndrome. However, WES
was negative for mutations in genes related to VHL, neurofibromatosis, and tuberous sclerosis. While the bilaterality and appearance of her lesions were similar to those observed in HIF-2α paragangioma-somatostatinoma-polycythemia syndrome, WES was also negative for a HIF-2α genetic mutation.

Over the next several years, the patient moved between several academic institutions, receiving monthly and, most recently, biweekly alternating bevacizumab and aflibercept intravitreal injections, as well as bimonthly Ozurdex injections. Only a small initial response was seen in the better eye. The lesions progressed to involve the papillomacular bundle. In early 2017, her vision had declined to 20/400 OD and no light-perception OS (Fig. 1). We performed a diagnostic enucleation of her left eye, with resulting pathology consistent with RRAT (Fig. 2). Genetic profiling of the mass did not show somatic HIF-2α mutation.

In late 2017, the patient was offered her first treatment of PDT, targeting an area nasal to the optic nerve with a resulting best corrected visual acuity 20/200 one month following treatment (Fig. 3). She subsequently received two more treatments to tissue surrounding the optic nerve superiorly, temporally, and inferiorly. This resulted in symptomatic improvement in vision and stabilization at 20/150, along with improvement of intra- and subretinal fluid and shrinkage of the tumor. Although the patient received several intravitreal anti-VEGF injections (aflibercept and bevacizumab) in the months following her last PDT treatment, the lesion has continued to decrease in size over the following two years without additional interventions.
2. Discussion

We present a young woman with bilateral optic nerve head tumors refractory to multiple interventions including frequent anti-VEGF injections. Her blind left eye was diagnostically enucleated, with immunohistochemistry positive for GFAP and S100 and histopathology consistent with RRAT. Right eye PDT was successful in stabilizing vision and shrinking the tumor.

There is controversy regarding the true nature of RRAT. Histopathology done by Poole Perry et al.6 demonstrated a relative paucity of the microvasculature compared to previous reports.2,5 This was also seen in our specimen. A change in the nomenclature from vascular proliferative tumor of the retina to the term "reactive retinal astrocytic tumor" has been suggested. Shields et al. have argued that the observed predominance of gliosis and relative lack of blood vessels is secondary to treatments including cryotherapy and multiple injections of anti-VEGF agents.7 By the time advanced cases were enucleated, they postulated that the vascular components would have regressed. Countering that argument, genetic profiling of these lesions demonstrated upregulation of genes seen in reactive astrocytes despite a general lack of upregulation of vascular and angiogenesis-related genes.7

There are several entities in the differential diagnosis of similar lesions. The initial appearance of apparent papilledema suggested a diagnosis of pseudotumor cerebri, leading to an optic nerve sheath biopsy with fenestration. However, the early age of onset and bilateral nature of the masses in the current patient were suggestive of a genetic cause. A strong resemblance to lesions observed in HIF-2α paraganglioma-somatostatinoma-polycythemia syndrome was noted.8 These somatic gain-of-function mutations in HIF-2α are associated with optic disc edema and fibrosis, bilateral dilated capillaries, and retinal exudates. Another potential diagnosis was bilateral hemangioblastomas associated with VHL syndrome, an entity also involving dysregulation of the HIF pathway. Classically, these tumors are found in young patients, who present with one or multiple tumors that can be bilateral and located anywhere in the retina.10 In contrast, RRATs occur sporadically in older patients, are unilateral, and are most often found in the retinal periphery.2 However, bilateral RRAT has been reported in the past (found in 4% of patients with primary RRAT, and 20% of patients with secondary RRAT).2 In addition, there are indications of a possible genetic etiology of RRAT as bilateral lesions have been reported in a pair of 58 year-old monozygotic female twins.11 While it is important to note that histopathology cannot definitively distinguish between RRAT and the ocular lesions observed in HIF-2α paraganglioma-somatostatinoma-polycythemia syndrome, the patient’s

Fig. 3. Clinical imaging before and after photodynamic therapy (PDT). Infrared (IR) fundus image of the right macula (A) and optic nerve (B) prior to PDT treatment. Yellow lines mark locations of associated optical coherence tomography (OCT) B-scans. Note substantial subretinal and intraretinal fluid in B-scan associated with (A) as well as the size of the optic nerve mass in B-scan associated with (B). Fluorescein angiography (C) prior to PDT treatment demonstrating areas of capillary drop-out as well as scattered telangiectatic vessels, which leak in late frames. IR and OCT B-scans of the macula (D) and optic nerve (E) depict significant improvement in edema twelve months after the last PDT session as well as significant improvement in size of the optic nerve mass. Color fundus photography pre- (F) and post-PDT (G) displaying slight apparent decrease in size of the lesion. The blue, green, and black circles approximately mark the sites of the first, second, and third PDT treatments respectively. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Histopathology was reviewed by several ocular pathologists who believed it to be more consistent with RRAT. In addition, our patient did not have systemic mutations in either the HIF-2α or VHL genes, the optic nerve mass did not show HIF-2α somatic mutations, and the patient did not present with evidence of a paraganglioma, a somatostatinoma, or polycythemia.

Another entity that was considered was retinal astrocytic hamartoma, which often presents bilaterally at the optic disc and is commonly associated with tuberous sclerosis complex. While these lesions are typically considered benign and relatively stable, aggressive cases necessitating enucleation have been documented. When these aggressive tumors are associated with tuberous sclerosis, they have been reported to occur adjacent to the optic disc with invasion of the optic nerve, but generally require enucleation early in childhood or adolescence and have histopathology characteristically demonstrating the presence of populations of giant cells resembling those seen in subependymal giant cell astrocytoma as well as significant necrosis, none of which were observed in the current case. In cases of aggressive retinal astrocytic hamartoma not associated with tuberous sclerosis, enucleation may be required at an older age but the lesions are generally unilateral. Overall given the histopathology and negative genetic testing for tuberous sclerosis and neurofibromatosis, retinal astrocytic hamartoma was considered lower on the differential diagnosis.

A variety of treatment modalities have been used for RRAT. These include cryopexy, anti-VEGF injections, and plaque radiotherapy, which have all demonstrated effectiveness in shrinking peripheral lesions as well as stabilizing or improving vision. Success using PDT has also been reported in peripheral tumors. In our case, years of anti-VEGF and steroid treatments failed to halt lesion growth and exudation, or improve visual acuity, but PDT resulted in resolution of fluid as well as tumor regression. Use of verteporfin in close proximity to the optic nerve (within 200 μm of the temporal edge of the optic disc) is specifically prohibited on the package labeling for fear of optic nerve vascular compromise and resulting vision loss. However, PDT has been utilized at the optic nerve in other conditions without subsequent evidence of optic nerve damage. In our case, to minimize this risk, staged treatments were guided by fluorescein angiography to tissue adjacent to the nerve.

In conclusion, we describe a unique presentation of bilateral optic disc RRAT refractory to steroids and anti-VEGF injections, where staged treatment with PDT was effective and safe.

Patient consent
The patient consented to publication of the case in writing.

Funding
No funding or grant support

Authorship
All authors attest that they meet the current ICMJE criteria for authorship.

Declaration of competing interest
The following authors have no financial disclosures (ACO, LMJ, AAF).

Acknowledgements
We would like to acknowledge and thank Dr. Paul J. Bryar for assisting with histopathology of this case. We would also like to acknowledge and thank Dr. Hans E. Grossniklaus for consulting on the histopathology.

References
1. Shields JA, Decker WL, Sanborn GE, Augsburger JJ, Goldberg RE. Presumed acquired retinal angiomas. Ophthalmology. 1983;90(11):1292–1300.
2. Shields CL, Shields JA, Barrett J, De Potter P. Vasoproliferative tumors of the ocular fundus. Classification and clinical manifestations in 103 patients. Arch Ophthalmol. 1995;113(5):615–623.
3. Shields CL, Kaliki S, Al-Dahmah S, et al. Retinal vasoproliferative tumors: comparative clinical features of primary vs secondary tumors in 334 cases. JAMA Ophthalmol. 2013;131(3):328–334.
4. Campochiaro PA, Conway BP. Hemangiomalous masses of the retina. JAMA Ophthalmol. 1988;106(10):1409–1413.
5. Heimann H, Bornfeld N, Vij G, et al. Vasoproliferative tumours of the retina. Br J Ophthalmol. 2005;89(10):1162–1169.
6. Poole Perry LJ, Jakobiec FA, Zakka FR, et al. Reactive retinal astrocytic tumors (so-called vasoproliferative tumors): histopathologic, immunohistochemical, and genetic studies of four cases. Am J Ophthalmol. 2013;155(3):593–608, e591.
7. Shethi M, Bouhenni R, Ghazi NG, Abu Safiieh L, Edward DP. Retinal reactive astrocytic tumor: gene expression profiling. JAMA Ophthalmol. 2014;132(6):773–775.
8. Pacak K, Chew EY, Pappo AS, et al. Ocular manifestations of hypoxia-inducible factor-2 alpha paraganglioma-somatostatinoma-polycythemia syndrome. Ophthalmology. 2014;121(11):2291–2293.
9. Shields JA, CL. Reactive retinal astrocytic tumors (so-called vasoproliferative tumors): histopathologic, immunohistochemical, and genetic studies of four cases. Am J Ophthalmol. 2013;156(1):202–203.
10. Irvine F, O’Donnell N, Kemp E, Lee WR. Retinal vasoproliferative tumors: surgical management and histological findings. Arch Ophthalmol. 2000;118(4):563–569.
11. Wachtlin J, Heimann H, Jandeck C, et al. Bilateral vasoproliferative retinal tumors with identical localization in a pair of monozygotic twins. Arch Ophthalmol. 2002;120(6):860–862.
12. Mutolo MG, Marciano S, Benassi F, Pardini M, Caratolo P, Emberti Giannotti L. Optical coherence tomography and infrared images of astrocytic hamartomas not revealed by funduscopic in tuberous sclerosis complex. Retina. 2017;37(7):1383–1392.
13. Shields JA, Eagle Jr RC, Shields CL, Marr BP. Aggressive retinal astrocytomas in four patients with tuberous sclerosis complex. Trans Am Ophthalmol Soc. 2004;102:139–147, discussion 147–158.
14. Kenawzy N, Groenwald C, Damato B. Treatment of a vasoproliferative tumour with intravitreal bevacizumab (Avastin). Eye. 2007;21(6):893–894.
15. Iliasi MA, Scupola A, Tiberti AC, Senso P, Balestrazzi E. Photodynamic therapy for vasoproliferative retinal tumours. Retina. 2006;26(4):404–409.
16. Schmidt-Erfurth UM, Kusserow C, Barbazetto IA, Lueski H. Benefits and complications of photodynamic therapy of papillary capillary hemangiomas. Ophthalmology. 2002;109(7):1256–1266.
17. Bernstein PS, Horn RS. Verteporfin photodynamic therapy involving the optic nerve for peripapillary choroidal neovascularization. Retina. 2008;28(1):81–84.